Along with delaying tumor formation, we were able to see in the immunocompetent Tgfbr1/Pten 2cKO mice that the IL-13-PE treatment could additionally limit the development of an immunosuppressive tumor environment. This evidence concerns the gene PTEN and neoplasm.